TY - JOUR
T1 - Radiomic Phenotypes for Improving Early Prediction of Survival in Stage III Non-Small Cell Lung Cancer Adenocarcinoma after Chemoradiation
AU - Luna, José Marcio
AU - Barsky, Andrew R.
AU - Shinohara, Russell T.
AU - Roshkovan, Leonid
AU - Hershman, Michelle
AU - Dreyfuss, Alexandra D.
AU - Horng, Hannah
AU - Lou, Carolyn
AU - Noël, Peter B.
AU - Cengel, Keith A.
AU - Katz, Sharyn
AU - Diffenderfer, Eric S.
AU - Kontos, Despina
N1 - Funding Information:
Funding: This work was partially supported by an award granted by the Emerson Collective, the Marlene Shlomchik Fellowship granted by the Abramson Cancer Center and pilot funding granted by the Penn Center for Precision Medicine.
Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/2/1
Y1 - 2022/2/1
N2 - We evaluate radiomic phenotypes derived from CT scans as early predictors of overall survival (OS) after chemoradiation in stage III primary lung adenocarcinoma. We retrospectively analyzed 110 thoracic CT scans acquired between April 2012−October 2018. Patients received a me-dian radiation dose of 66.6 Gy at 1.8 Gy/fraction delivered with proton (55.5%) and photon (44.5%) beam treatment, as well as concurrent chemotherapy (89%) with carboplatin-based (55.5%) and cis-platin-based (36.4%) doublets. A total of 56 death events were recorded. Using manual tumor seg-mentations, 107 radiomic features were extracted. Feature harmonization using ComBat was performed to mitigate image heterogeneity due to the presence or lack of intravenous contrast material and variability in CT scanner vendors. A binary radiomic phenotype to predict OS was derived through the unsupervised hierarchical clustering of the first principal components explaining 85% of the variance of the radiomic features. C-scores and likelihood ratio tests (LRT) were used to com-pare the performance of a baseline Cox model based on ECOG status and age, with a model integrating the radiomic phenotype with such clinical predictors. The model integrating the radiomic phenotype (C-score = 0.69, 95%CI = (0.62, 0.77)) significantly improved (< 0.005) upon the baseline model (C-score = 0.65, CI = (0.57, 0.73)). Our results suggest that harmonized radiomic phenotypes can significantly improve OS prediction in stage III NSCLC after chemoradiation.
AB - We evaluate radiomic phenotypes derived from CT scans as early predictors of overall survival (OS) after chemoradiation in stage III primary lung adenocarcinoma. We retrospectively analyzed 110 thoracic CT scans acquired between April 2012−October 2018. Patients received a me-dian radiation dose of 66.6 Gy at 1.8 Gy/fraction delivered with proton (55.5%) and photon (44.5%) beam treatment, as well as concurrent chemotherapy (89%) with carboplatin-based (55.5%) and cis-platin-based (36.4%) doublets. A total of 56 death events were recorded. Using manual tumor seg-mentations, 107 radiomic features were extracted. Feature harmonization using ComBat was performed to mitigate image heterogeneity due to the presence or lack of intravenous contrast material and variability in CT scanner vendors. A binary radiomic phenotype to predict OS was derived through the unsupervised hierarchical clustering of the first principal components explaining 85% of the variance of the radiomic features. C-scores and likelihood ratio tests (LRT) were used to com-pare the performance of a baseline Cox model based on ECOG status and age, with a model integrating the radiomic phenotype with such clinical predictors. The model integrating the radiomic phenotype (C-score = 0.69, 95%CI = (0.62, 0.77)) significantly improved (< 0.005) upon the baseline model (C-score = 0.65, CI = (0.57, 0.73)). Our results suggest that harmonized radiomic phenotypes can significantly improve OS prediction in stage III NSCLC after chemoradiation.
KW - ComBat
KW - Computed tomography
KW - Non-small cell lung cancer
KW - Overall survival
KW - Radiomics
UR - http://www.scopus.com/inward/record.url?scp=85123538590&partnerID=8YFLogxK
U2 - 10.3390/cancers14030700
DO - 10.3390/cancers14030700
M3 - Article
C2 - 35158971
AN - SCOPUS:85123538590
SN - 2072-6694
VL - 14
JO - Cancers
JF - Cancers
IS - 3
M1 - 700
ER -